Key result
Each 50-meter increase in 6MWD is linked to ~17% lower MACE risk in CVD patients.
Why the study?
The prognostic value of the six-minute walk test to predict the incidence of MACE in patients with cardiovascular disease required evaluation.
Does baseline six-minute walk test distance predict major adverse cardiovascular events in patients with prevalent cardiovascular disease?
Population
1,374 patients with prevalent cardiovascular diseases in a cardiac rehabilitation registry
Comparison
Baseline 6MWT distance
Design
Registry-based cohort study
Authors
Loading...
May aid MACE risk stratification in CVD; leaves open incremental value over standard models.
Observational (n=1,374)
No
Does baseline six-minute walk test distance predict major adverse cardiovascular events in patients with prevalent cardiovascular disease?
Effect estimate: HR 0.831
p-value: p=<0.001
The six-minute walk test is a strong prognostic indicator for MACE in patients with cardiovascular disease, and applying disease-specific distance cutoffs improves predictive accuracy.
Sohn et al. (2025) conducted an observational in Cardiovascular disease (n=1,374). Six-minute walk test (6MWT) vs. Shorter distance was evaluated on Major adverse cardiovascular events (MACE) (HR 0.831, p=<0.001). Each 50-meter increase in the 6-minute walk test distance was associated with a significantly lower risk of major adverse cardiovascular events (HR 0.831) in patients with cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: